步長製藥(603858.SH):宣肺敗毒顆粒獲批烏茲別克斯坦上市
格隆匯5月9日丨步長製藥(603858.SH)公佈,近日,山東步長製藥股份有限公司收到烏茲別克斯坦共和國衞生部核准簽發的藥物註冊批准文件,批准公司藥品宣肺敗毒顆粒符合烏茲別克斯坦藥物標準註冊。
宣肺敗毒顆粒為公司2021年獲批上市的獨家品種,經談判已納入《國家基本醫療保險、工傷保險和生育保險藥品目錄(2021年)》。功能主治為:宣肺化濕,清熱透邪,瀉肺解毒。用於濕毒鬱肺所致的疫病。症見發熱,咳嗽,咽部不適,喘促氣短,乏力,納呆,大便不暢;舌質暗紅,苔黃膩或黃燥,脈滑數或弦滑。根據國家衞生健康委員會辦公廳和國家中醫藥管理局辦公室聯合發佈的《新型冠狀病毒肺炎診療方案(試行第九版)》,宣肺敗毒顆粒被列為臨牀治療期(確診病例)普通型推薦用藥。
截至公吿披露日,宣肺敗毒顆粒的銷售收入為2293.70萬元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.